Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) will be posting its Q114 quarterly earnings results on Thursday, April 24th. Analysts expect Alexion Pharmaceuticals to post earnings of $1.26 per share and revenue of $560.22 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. On average, analysts expect Alexion Pharmaceuticals to post $4.49 EPS for the current fiscal year and $5.38 EPS for the next fiscal year.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 156.10 on Wednesday. Alexion Pharmaceuticals has a 1-year low of $87.01 and a 1-year high of $185.43. The stock has a 50-day moving average of $159. and a 200-day moving average of $140.6. The company has a market cap of $30.881 billion and a price-to-earnings ratio of 119.83.

Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday. On the ratings front, analysts at Credit Suisse raised their price target on shares of Alexion Pharmaceuticals to $171.00 in a research note on Thursday, March 27th. They now have a “neutral” rating on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of Alexion Pharmaceuticals from $175.00 to $199.00 in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $181.88.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.